BRAF and melanoma: Using BRAF mutant melanoma cell models, we demonstrate that although CDK4/6 inhibition does not alter the metabolic phenotype following BRAF/MEK inhibition, CDK4/6 inhibition alone significantly enhances mitochondrial metabolism.